Author

L. M. Cooper

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1

Frequent Co-Authors

A. B. Malik· 1 shared A. F. Gugliuzza· 1 shared C. L. Ramage· 1 shared CTD2 Research Network· 1 shared D. Shukla· 1 shared E. Procko· 1 shared G. B. Mills· 1 shared J. N. Sarkaria· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. B. Malik

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML

V. Mohanty, N. Baran, Y. Huang, C. L. Ramage, L. M. Cooper, S. He, R. Iqbal, M. Daher, CTD2 Research Network, J. W. Tyner, G. B. Mills, M. Konopleva, K. Chen

This study identifies four transcriptionally distinct venetoclax-resistant clusters in AML, revealing phenotypic, genetic, and drug response differences and their implications for treatment resistance.

bioRxiv · Jan 27, 2024 · PreprintCancer Biology

Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants

L. Zhang, S. Dutta, S. Xiong, M. Chan, K. K. Chan, T. M. Fan, K. L. Bailey, M. Lindeblad, L. M. Cooper, L. Rong, A. F. Gugliuzza, D. Shukla, E. Procko, J. Rehman, A. B. Malik

This study shows an engineered ACE2 peptide effectively mitigates ARDS and death in mice infected with multiple SARS-CoV-2 variants.

bioRxiv · Dec 21, 2021Pharmacology & Toxicology

A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma

W.-H. Lin, R. W. Feathers, L. M. Cooper, L. Lewis-Tuffin, J. N. Sarkaria, P. Z. Anastasiadis

This study identifies a Syx-RhoA-Dia1-YAP/TAZ signaling axis that promotes glioblastoma growth, DNA damage, and therapy resistance, suggesting it as a therapeutic target.

bioRxiv · Dec 3, 2021Cancer Biology